D053245Chemicals & DrugsD12.644.276.374.750.562D12.644.276.972.562D12.776.467.374.750.562D12.776.467.972.562D23.529.374.750.562D23.529.972.562440.998973RANK LigandFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonWake Forest School of MedicineJeffreyWilleyJeffrey S. Willey PhD36.09103700000000-80.269096000000001392Willey, JeffreyAssistant ProfessorJ.ClineJ. M. Cline DVM, PhD36.08943500000000-80.26863200000000447Cline, J.ProfessorThomasRegisterThomas C. Register PhD36.08943500000000-80.26863200000000803Register, ThomasProfessor26030441Goyden J, Tawara K, Hedeen D, Willey JS, Oxford JT, Jorcyk CLPloS oneGoyden J, Tawara K, Hedeen D, Willey JS, Oxford JT, Jorcyk CL. The Effect of OSM on MC3T3-E1 Osteoblastic Cells in Simulated Microgravity with Radiation. PLoS One. 2015; 10(6):e0127230.PLoS One2015-06-01T00:00:002015The Effect of OSM on MC3T3-E1 Osteoblastic Cells in Simulated Microgravity with Radiation.21646612Sorscher SM, Lockhart ACJournal of clinical oncology : official journal of the American Society of Clinical OncologySorscher SM, Lockhart AC. Ras inhibition and the survival benefit favoring zoledronic acid compared with denosumab in patients with multiple myeloma. J Clin Oncol. 2011 Jul 01; 29(19):2735-6; author reply 2736-8.J Clin Oncol2011-06-06T00:00:002011Ras inhibition and the survival benefit favoring zoledronic acid compared with denosumab in patients with multiple myeloma.GaganDeepGagan Deep PhD36.09032400000000-80.266491000000001924Deep, GaganProfessor23115104Kavitha CV, Deep G, Gangar SC, Jain AK, Agarwal C, Agarwal RMolecular carcinogenesisKavitha CV, Deep G, Gangar SC, Jain AK, Agarwal C, Agarwal R. Silibinin inhibits prostate cancer cells- and RANKL-induced osteoclastogenesis by targeting NFATc1, NF-?B, and AP-1 activation in RAW264.7 cells. Mol Carcinog. 2014 Mar; 53(3):169-80.Mol Carcinog2012-10-31T00:00:002012Silibinin inhibits prostate cancer cells- and RANKL-induced osteoclastogenesis by targeting NFATc1, NF-?B, and AP-1 activation in RAW264.7 cells.26659358Qiao M, Wu D, Carey M, Zhou X, Zhang LPloS oneQiao M, Wu D, Carey M, Zhou X, Zhang L. Multi-Scale Agent-Based Multiple Myeloma Cancer Modeling and the Related Study of the Balance between Osteoclasts and Osteoblasts. PLoS One. 2015; 10(12):e0143206.PLoS One2015-12-11T00:00:002015Multi-Scale Agent-Based Multiple Myeloma Cancer Modeling and the Related Study of the Balance between Osteoclasts and Osteoblasts.22Associate ProfessorInternal Medicine, Gerontology & Geriatric MedicineInternal Medicine, RheumatologyPathology, Comparative Medicinetrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessortrue1ProfessorProfessor21229838Jones KW, Bushardt RLJAAPA : official journal of the American Academy of Physician AssistantsJones KW, Bushardt RL. ... Fracture prevention. New osteoporosis drug improves patient adherence. JAAPA. 2010 Dec; 23(12):56, 60.JAAPA2010-12-01T00:00:002010... Fracture prevention. New osteoporosis drug improves patient adherence.0.1138810.02880714research area of0.4559910.1120467subject area for